ArticleBMC pediatrics2026
Long-term endocrine complications and quality of life in pediatric-onset craniopharyngioma: a single-center cohort study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCraniopharyngioma is a benign yet locally aggressive brain tumor that causes substantial long-term endocrine, metabolic, visual, and hypothalamic morbidities, leading to impaired quality of life (QoL). However, data on QoL and long-term outcomes in Thai pediatric patients remain limited.
methodsThis study included two components: a retrospective cohort review of long-term endocrine, metabolic, and visual outcomes in patients aged ≤ 25 years with histologically confirmed pediatric-onset craniopharyngioma diagnosed between 2000 and 2023 at Siriraj Hospital, and a cross-sectional assessment of quality of life using the Pediatric Quality of Life Inventory (PedsQL 4.0). Factors associated with quality of life were evaluated using linear regression.
resultsEighteen patients were included (median age at diagnosis 6.8 years). Postoperative endocrine deficiencies were common, including growth hormone deficiency (88.9%), vasopressin deficiency (100%) and gonadotropin deficiency (93.3% of evaluable patients). Residual/recurrent disease developed in 55.6% of patients during follow-up. Metabolic complications were common, overweight and obesity at recent follow-up were observed in 6 (33.3%) and 4 (22.2%) patients, respectively. Among screened patients (88.9%), dyslipidemia occurred in 62.5%, metabolic dysfunction-associated steatotic liver disease in 25.0%, and type 2 diabetes in one patient. Height SDS declined and BMI SDS increased significantly over time (p < 0.05). Visual impairment progressed in 27.8%. The mean PedsQL score was 68.8 ± 15.2. In exploratory analyses, obesity was associated with poorer quality of life.
conclusionsPediatric craniopharyngioma carries a substantial burden of long-term endocrine, metabolic, and visual morbidity, adversely affecting growth and quality of life. Lifelong, multidisciplinary follow-up is essential to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.